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Seldom in medical history has a single clinical entity created
greater havoc among a diversity of interests and individuals
than drug-induced long QT syndrome (diLQTS) (1). Drug
companies have witnessed powerful molecules, developed at
extraordinary costs, that were suddenly withdrawn from the
market after only a few cases of sudden cardiac death or life-
threatening arrhythmias caused by therapeutic doses of very
promising drugs. Regulatory agencies were confused. In-
dividuals have experienced cardiac arrest while being treated
for diseases as benign as hay fever (2–4). Physicians and sci-
entists have been puzzled by this phenomenon for almost 100
years (5).
See page 1430
The prototype of diLQTS has unquestionably been
quinidine syncope (6,7). It was indeed the attention gener-
ated by quinidine syncope, largely related to the fact that this
was the only antiarrhythmic drug effective in the manage-
ment of atrial ﬁbrillation (8), that prompted the identiﬁca-
tion of 2 key features: prolongation of the QT interval and
torsades de pointes ventricular tachycardia. Both features
could have immediately suggested a link with congenital
long QT syndrome (cLQTS), but it was only in 1982 that
Schwartz and Moss (9), anticipating the molecular era,
posited for the ﬁrst time that “quinidine therapy may exac-
erbate an underlying repolarization abnormality, possibly a
subclinical forme fruste of idiopathic LQTS with incomplete
expression”. By the elegant use of the French language, they
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paper to disclose.borderline QT interval. It took 20 years to go from hy-
pothesis to proof of concept.
The identiﬁcation of the ﬁrst major genes for LQTS took
place in 1995 to 1996 and has had a major impact on the
approach and management of channelopathies in general
and of LQTS in particular (10), thus opening the ﬁeld for
the attempts to uncover the genetic basis of the relationship
between drug-induced syncope, QT interval prolongation,
and cLQTS. The ﬁrst such evidence was obtained when an
elderly woman with cardiac arrest due to documented ven-
tricular ﬁbrillation associated with treatment with cisapride,
a well-known cardiac delayed rectiﬁer potassium current
(IKr) blocker, was found to have the KCNQ1-Y315C mu-
tation (11). Her baseline corrected QT interval was normal
(430 to 437 ms) but was prolonged on cisapride to 530
to 590 ms, just before and after ventricular ﬁbrillation; it
normalized completely after cisapride withdrawal, and we
demonstrated that the mutant protein produces a major loss
in the cardiac slow delayed potassium rectiﬁer current (IKs)
current (11). This single case provided the ﬁrst evidence that
“silent” genetic defects may create a vulnerable substrate that,
in the presence of appropriate triggers such as any drug that
blocks IKr, may precipitate life-threatening arrhythmias and
raised the intriguing possibility that some of the individuals
at risk of diLQTS might in the future be identiﬁed by a still-
unforeseen genetic approach. It also supported the very
important concept of repolarization reserve, cleverly pro-
posed by Roden (12) and the “2-hit” hypothesis implying
the possibility of a genetic impairment in IKs increasing the
risk of diLQTS on administration of an IKr blocker (13).
What followed was a dramatic acceleration in the search for
the genetic link between drugs and diLQTS. Several groups
contributed in a major way, among them, those led by Dan
Roden (14,15), undoubtedly the investigator who has contrib-
uted more than anyone else to this speciﬁc topic, by Kääb et al.
(16), and byHorie’s group (17,18). This leads us to this issue of
the Journal, in which Weeke et al. (19) used whole exome
sequencing (WES) to detect genes contributing to diLQTS.
Weeke et al. studied 65 patients and 2 sets of control
subjects: 148 drug-exposed control subjects and a reference
group of 515 nonphenotyped individuals from the Exome
Sequencing Project (ESP), with the focus on European-
American ancestry. Given the small sample size and the
consequent small power, they cleverly used different sets of
analysis, progressively less stringent. They started by
checking the number of amino acid coding (AAC) variants
(missense, nonsynonymous, or frameshift), and they used
it to identify the Bonferroni-adjusted p value (p < 6.39 
107). By the Fisher exact test and exact logistic regression,
no single AAC variant reached that genome-wide signiﬁ-
cance threshold. They then moved from the number of
AAC variants to the number of genes containing those
variants to test for gene-level association, and the
Bonferroni-adjusted p value was accordingly increased to
p < 3.5  106. Unidirectional (variable threshold) and
bidirectional (sequence kernel association test) rare variant
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single gene carrying AAC variants reached the threshold for
signiﬁcance. This negative result was interpreted as due to
the likelihood that the study was underpowered for a
genome-wide approach, and, accordingly, they applied a
third analysis looking only at those genes with the strongest
associations identiﬁed by variable threshold and sequence
kernel association test. Empirically, a p < 0.001 was
considered to select the “top” genes, and then the associa-
tion was retested comparing the same group of patients with
the 515 individuals from the ESP. For the validation, the
investigators had to reduce the p value from 0.001 to 0.05,
clearly to avoid losing the signiﬁcance on the KCNE1 gene
already established (16). This approach is acceptable but is
signiﬁcantly limited by the absence of an independent
population of cases and controls, which represents the gold
standard for validation studies.
This staircase analysis led to the identiﬁcation of 2 genes
important for diLQTS: KCNE1, already known for its as-
sociation with diLQTS (16,18), and ACN9, a gene whose
association with diLQTS needs to be elucidated and sup-
ported by further studies. Finally, they limited their analysis
to 20 genes with a strong level of evidence of association
with congenital arrhythmia syndromes, and they looked at
genes enriched with rare variants among diLQTS patients
versus drug-exposed control subjects and versus ESP control
subjects. Importantly, patients with diLQTS had a 2-fold
enrichment of rare AAC variants in potassium channels
compared with drug-exposed and ESP control subjects; this
greater enrichment remained present after exclusion of
KCNE1.
The study by Weeke et al. (19) represents a good example
of how the WES technique can be used successfully, not
only for the identiﬁcation of new disease-causing genes, but
also for the identiﬁcation of rare variants modifying the
susceptibility to complex traits.
After the ﬁrst report in 2009 of selective WES in 12
humans (20), and the subsequent evidence that this method
could successfully identify a gene responsible for a rare
Mendelian disorder (21),>150 articles were published about
gene discovery by WES in various Mendelian disorders (22).
Three main approaches have been used so far to identify
disease-associated genes through WES: family-based
studies, case-parent trio studies, and unrelated individual
studies.
In family-based studies, a number of affected individuals
within a family are sequenced, and the shared mutations are
analyzed and prioritized according to the supposed way of
inheritance (i.e., autosomal dominant, autosomal recessive,
or X linked). Examples are the identiﬁcation of a GATAD1
mutation as the cause of a form of autosomal recessive car-
diomyopathy (23) and the segregation of 2 private mutations
in 2 functionally related genes (GUCY1A3 and CCT7) in an
extended myocardial infarction family (24).
Case-parent trio studies are used to identify mutations
responsible for very severe disorders not expected to beinherited from the parents. Both the parents and the proband
are fully exome-sequenced, and the de novo novel variants
identiﬁed become the main focus of the analysis. An example
is the identiﬁcation of mutations in calmodulin genes
responsible for an extremely malignant form of cLQTS (25).
Zaidi et al. (26) used a similar approach, but with a case-
control analysis, and observed a marked excess of protein-
altering de novo mutations in histone-modifying genes in
patients with congenital heart diseases.
WES studies in unrelated individuals, as in the study by
Weeke et al. (19), are more challenging but can be applied
to a variety of questions. For example, Ng et al. (27), with
only 10 unrelated subjects affected by the Kabuki syndrome
in the discovery cohort and 43 affected individuals in the
replication cohort, were able to identify MML2 as the major
gene responsible for this rare multiple malformation disor-
der. These successful studies based on a few unrelated in-
dividuals are possible mainly in monogenic disorders with
minimal genetic heterogeneity. The same case-control
approach proved successful also for the identiﬁcation of
genetic pathways/variants enriched in complex traits (28,29).
In line with these studies on complex traits and with the
emerging shift from a common disease–common variant
hypothesis to a rare variant–common disease/complex trait
hypothesis (30), Weeke et al. (19) used a case-control
approach to identify genes or gene pathways favoring the
risk of diLQTS. The validity of this approach appears to be
conﬁrmed by the identiﬁcation of KCNE1 rare variants, as
factors favoring the risk of diLQTS, as already demonstrated
by Kääb et al. (16). The modest overlapping of the 2 studies
does not detract from the ﬁnding.
The data of Weeke et al. (19) complement well those of
Behr et al. (31) showing a failure of a genome-wide asso-
ciation study approach to identify common variants
conferring a high risk of diLQTS, and suggest that rare
variants indeed play a prominent role. The small sample size
of the study by Behr et al. (31) does not allow excluding that
the interaction of multiple variants with a modest individual
effect might also contribute to this complex and uncommon
phenotype.
The study by Weeke et al. (19), as it often happens with
those led by Roden, may open interesting windows on the
future. The WES technique, born as a very expensive tool
aimed at the identiﬁcation of new disease-causing genes
mainly in Mendelian disorders, has progressively shown
potential for going well beyond. It is becoming progressively
less expensive with a constant improvement in its gene-
coverage capability, possibly overcoming also the initial
limitation in the identiﬁcation of copy number variants (32).
One could thus envisage that WES might become useful
for the combined study of disease-causing and modiﬁer
factors and could replace existing genetic screening pro-
grams in clinical practiceda step toward the dream of a
single test providing complete genetic information for a
fully comprehensive tailored medicine. Things are actually
moving very rapidly now. The U.S. Food and Drug
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the ﬁrst high-throughput genome sequencer (Illumina’s
MiSeqDx), which will allow the development and use of
innumerable new genome-based tests. As Collins and
Hamburg (33) have rightly stated, “this marketing author-
ization.represents a signiﬁcant step forward in the ability
to generate genomic information that will ultimately
improve patient care.”
The speed of the progress in the genetics of cardiac ar-
rhythmias has been mind-boggling and, not infrequently,
disconcertingly exciting. Still, it is a refreshing and soothing
thought, at least for some of us, to realize that the directions
for the future sometimes can be pointed out by the long
shadows of the past.
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